ATE428427T1 - Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten - Google Patents

Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten

Info

Publication number
ATE428427T1
ATE428427T1 AT04777596T AT04777596T ATE428427T1 AT E428427 T1 ATE428427 T1 AT E428427T1 AT 04777596 T AT04777596 T AT 04777596T AT 04777596 T AT04777596 T AT 04777596T AT E428427 T1 ATE428427 T1 AT E428427T1
Authority
AT
Austria
Prior art keywords
sub
receptor antagonists
gonadotropin
releasing hormone
pyrimidine
Prior art date
Application number
AT04777596T
Other languages
English (en)
Inventor
Yun-Fei Zhu
Collin Regan
Jaimie Rueter
Zhiqiang Guo
Yongsheng Chen
Charles Huang
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Application granted granted Critical
Publication of ATE428427T1 publication Critical patent/ATE428427T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04777596T 2003-07-07 2004-07-06 Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten ATE428427T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48543603P 2003-07-07 2003-07-07
PCT/US2004/021569 WO2005007164A1 (en) 2003-07-07 2004-07-06 Pyrimidine-2,4-dione derivatives as gonadotropin-releasing hormone receptor antagonists

Publications (1)

Publication Number Publication Date
ATE428427T1 true ATE428427T1 (de) 2009-05-15

Family

ID=34079122

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04777596T ATE428427T1 (de) 2003-07-07 2004-07-06 Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten

Country Status (14)

Country Link
US (2) US7071200B2 (de)
EP (1) EP1660091B1 (de)
JP (2) JP4658044B2 (de)
KR (1) KR20060052790A (de)
CN (2) CN100376246C (de)
AT (1) ATE428427T1 (de)
AU (1) AU2004257636B2 (de)
BR (1) BRPI0412327A (de)
CA (1) CA2531507C (de)
DE (1) DE602004020638D1 (de)
EA (1) EA200600188A1 (de)
IL (1) IL172834A0 (de)
MX (1) MXPA06000300A (de)
WO (1) WO2005007164A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU767585B2 (en) * 2000-01-25 2003-11-20 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
ATE557007T1 (de) * 2003-07-07 2012-05-15 Neurocrine Biosciences Inc Arylpyrimidine geeignet zur behandlung von sexualhormonbedingten zuständen wie endometriose, prostatakrebs und dergleichen
EP1646389B1 (de) * 2003-07-07 2008-09-10 Neurocrine Biosciences, Inc. Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten
CN102127053A (zh) * 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
JP2008534500A (ja) 2005-03-24 2008-08-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ プロキネチシン１受容体アンタゴニスト
WO2006102112A2 (en) 2005-03-24 2006-09-28 Janssen Pharmaceutica N.V. Prokineticin 1 receptor
KR100837785B1 (ko) * 2007-01-17 2008-06-13 한국화학연구원 1,2,4-티아다이아졸리딘-3,5-다이온 화합물을 포함하는염증관련 질환의 치료 및 예방을 위한 약제학적 조성물
NZ580457A (en) 2007-04-06 2012-03-30 Neurocrine Biosciences Inc Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
WO2008124614A1 (en) 2007-04-06 2008-10-16 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US8765948B2 (en) 2007-11-07 2014-07-01 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
EP2390250B1 (de) * 2009-11-20 2015-08-12 Sk Chemicals Co., Ltd. Gonadotropin freisetzende hormonrezeptorantagonisten, verfahren zu ihrer herstellung und pharmazeutische zusammensetzung damit
TW201130854A (en) 2009-12-22 2011-09-16 Bayer Schering Pharma Ag Pyridinone derivatives and pharmaceutical compositions thereof
WO2012175514A1 (en) 2011-06-21 2012-12-27 Bayer Intellectual Property Gmbh Pyridinone derivatives and pharmaceutical compositions thereof
CN107935863A (zh) * 2017-11-30 2018-04-20 厦门海乐景生化有限公司 Elagolix的关键原料化合物C的合成方法
EP3724167A1 (de) * 2017-12-11 2020-10-21 Synthon B.V. Verfahren zur herstellung von elagolix
BR112021000973A2 (pt) 2018-07-23 2021-04-20 Abbvie Inc. composições e processos de sódio de elagolix
WO2020240375A1 (en) * 2019-05-24 2020-12-03 Dr. Reddy’S Laboratories Limited Improved process for the preparation of elagolix and its intermediates
ES2802815B2 (es) 2019-07-12 2022-03-14 Moehs Iberica Sl Sal clorhidrato de 3-[2(r)-amino-2-feniletil]-5-(2-fluoro-3-metoxifenil)-1-[2-fluoro-6-(trifluorometil)bencil]-6-metil-1h-pirimidin-2,4(1h,3h)-diona (i) en forma solida, procedimiento para su preparacion y uso de la misma en la sintesis de elagolix
CN112300081A (zh) * 2019-07-31 2021-02-02 上海度德医药科技有限公司 噁拉戈利的中间体及其制备方法和应用
CN112694445B (zh) * 2019-10-22 2023-07-28 成都倍特药业股份有限公司 一种噁拉戈利钠中间体的纯化方法
ES2822398B2 (es) 2019-10-30 2022-03-02 Moehs Iberica Sl 3-((R)-2-(Amino-2-feniletil)-1-(2-fluoro-6-trifluorometilbencil)-5-yodo-6-metil-1H-pirimidin-2,4-diona o una sal de la misma, procedimiento para su preparación y su uso en la síntesis de elagolix
CN110938038A (zh) * 2019-11-14 2020-03-31 上海星酶生物科技有限公司 一种c13h10f4n2o2的制备工艺
CN111333586A (zh) * 2020-02-19 2020-06-26 诚达药业股份有限公司 一种含有6-甲基尿嘧啶结构化合物的制备方法
CN111333587B (zh) * 2020-04-11 2023-04-07 东莞市东阳光新药研发有限公司 取代的嘧啶-2,4(1h,3h)-二酮衍生物及其用途
CN113527213B (zh) * 2020-04-20 2023-01-03 上海英诺富成生物科技有限公司 促性激素释放激素受体拮抗剂及其用途
CN111574461A (zh) * 2020-05-29 2020-08-25 奥锐特药业股份有限公司 一种噁拉戈利中间体的成盐纯化方法及获得的噁拉戈利中间体精品

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038438A1 (en) 1995-06-01 1996-12-05 Takeda Chemical Industries, Ltd. TRICYCLIC DIAZEPINES USEFUL AS GnRH RECEPTOR ANTAGONISTS
US5859014A (en) * 1995-06-09 1999-01-12 Syntex (U.S.A.) Inc. Pyrimidinedione, pyrimidinetrione, triazinedione and tetrahydroquinazolinedione derivatives as α1 -adrenergic receptor antagonists
CN1063446C (zh) 1995-10-19 2001-03-21 武田药品工业株式会社 作为促性腺激素释放激素拮抗剂的噻吩并吡啶衍生物
DE69623655T2 (de) 1995-10-19 2003-04-24 Takeda Chemical Industries, Ltd. Chinolinderivate als gnrh antagonisten
SK77498A3 (en) 1995-12-14 1999-01-11 Merck & Co Inc Nonpeptide derivatives, pharmaceutical composition containing them and their use
JP3092947B2 (ja) 1995-12-14 2000-09-25 メルク エンド カンパニー インコーポレーテッド ゴナドトロピン放出ホルモン拮抗剤
IL124613A0 (en) 1995-12-14 1998-12-06 Merck & Co Inc Antagonists of gonadotropin releasing hormone
DE69620241T2 (de) 1995-12-14 2002-10-02 MERCK & CO., INC. (A NEW JERSEY CORP.) Gonadotropin releasing hormon- antagonisten
JP2002503252A (ja) 1997-06-05 2002-01-29 メルク エンド カンパニー インコーポレーテッド ゴナドトロピン放出ホルモンの拮抗薬
JP2002502422A (ja) 1997-06-05 2002-01-22 メルク エンド カンパニー インコーポレーテッド ゴナドトロピン放出ホルモンの拮抗薬
AU728988B2 (en) 1997-06-05 2001-01-25 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
EP0986550A1 (de) 1997-06-05 2000-03-22 Merck & Co., Inc. Antagonisten des gonadotropin freisetzenden hormons
US6313301B1 (en) 1997-08-13 2001-11-06 Takeda Chemical Industries, Ltd. Thienopyridine derivatives, their intermediates and production thereof
CA2372044A1 (en) 1999-05-14 2000-11-23 Neurocrine Biosciences, Inc. Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
US20020065309A1 (en) 1999-08-04 2002-05-30 Ge Peng Novel Bicyclic and tricyclic pyrrolidine derivatives as GnRH antagonists
ES2249302T3 (es) 1999-10-15 2006-04-01 Neurocrine Biosciences, Inc. Antagonistas del receptor de la hormona liberadora de gonadotropina y sus metodos de uso relacionados.
AU767585B2 (en) * 2000-01-25 2003-11-20 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
SE0100566D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
AU2002321878A1 (en) 2001-08-02 2003-02-17 Neurocrine Biosciences, Inc. Pyridinone and pyridazinone derivatives as gonadotropin-releasing hormone receptor antagonists
EP1412363A1 (de) 2001-08-02 2004-04-28 Neurocrine Biosciences, Inc. Rezeptor antagonisten für gonadotropin-freisetzende hormone
AU2002324586B2 (en) 2001-08-02 2008-04-24 Neurocrine Biosciences, Inc. 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists
JP2005505525A (ja) 2001-08-02 2005-02-24 ニューロクライン バイオサイエンシーズ， インコーポレイテッド 性腺刺激ホルモン放出ホルモンレセプターアンタゴニストおよびそれに関連する方法
CA2455235A1 (en) 2001-08-02 2003-02-13 Joseph Pontillo 1,2,4-triazin-3,5-diones as gonadotropin-releasing hormone receptor (gnrh) antagonists
ATE557007T1 (de) 2003-07-07 2012-05-15 Neurocrine Biosciences Inc Arylpyrimidine geeignet zur behandlung von sexualhormonbedingten zuständen wie endometriose, prostatakrebs und dergleichen
EP1646389B1 (de) 2003-07-07 2008-09-10 Neurocrine Biosciences, Inc. Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten

Also Published As

Publication number Publication date
IL172834A0 (en) 2006-06-11
WO2005007164A1 (en) 2005-01-27
DE602004020638D1 (de) 2009-05-28
US7329669B2 (en) 2008-02-12
JP4658044B2 (ja) 2011-03-23
CN100376246C (zh) 2008-03-26
CN101229165A (zh) 2008-07-30
US20070015778A1 (en) 2007-01-18
JP2007521308A (ja) 2007-08-02
AU2004257636A1 (en) 2005-01-27
AU2004257636B2 (en) 2011-01-06
CA2531507C (en) 2013-10-01
CA2531507A1 (en) 2005-01-27
EP1660091A1 (de) 2006-05-31
EP1660091B1 (de) 2009-04-15
US20050043338A1 (en) 2005-02-24
EA200600188A1 (ru) 2006-08-25
CN1826119A (zh) 2006-08-30
BRPI0412327A (pt) 2006-09-05
US7071200B2 (en) 2006-07-04
JP2011088903A (ja) 2011-05-06
MXPA06000300A (es) 2006-03-28
KR20060052790A (ko) 2006-05-19

Similar Documents

Publication Publication Date Title
ATE407679T1 (de) Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten
ATE428427T1 (de) Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten
ATE548357T1 (de) Gonadotropin freisetzende hormon rezeptor antagonisten und ihre verwandten verfahren
WO2003011293A3 (en) Pyridinone and pyridazinone derivatives as gonadotropin-releasing hormone receptor antagonists
DE60022769D1 (de) Gonadotropin freisetzenden hormon rezeptor antagonisten und ihre verwandten verwendungen
IL142893A0 (en) Fused polyclic heterocyclic compounds and pharmaceutical compositions containing the same
ATE359791T1 (de) Pyrimidin-2,4-dion-derivate als matrix- metalloproteinase-hemmer
ATE557007T1 (de) Arylpyrimidine geeignet zur behandlung von sexualhormonbedingten zuständen wie endometriose, prostatakrebs und dergleichen
DE60208803D1 (de) 1,3,5-triazine-2,4,6-trione, herstellung und anwendungen als antagonisten der gonadotropin-freisetzenden hormonrezeptoren
DE60215637D1 (de) Tri- und tetraaza-acenaphthylen-derivate als crf-rezeptor-antagonisten
IS2424B (is) Þíenó[2,3-d]pýrimidín með sameinaðri LH og FSH gerandefnisvirkni
HK1072935A1 (en) Condensed camptothecins as antitumor agents
AU2001261850A1 (en) Crf receptor antagonists and methods relating thereto
AU2001263329A1 (en) Crf receptor antagonists and methods relating thereto
DE60314158D1 (de) Pyrazolderivate als gnrh-inhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties